invisible

Arnaud is a growth-focused senior executive and CEO with solid credentials in operational as well as strategic functions in the pharma, medical devices, diagnostics and laboratory supplies industries.

Combining strong analytical skills with strategic vision and an extensive international experience on all continents, he is capable of formulating and executing successful international growth strategies and go-to-market value propositions. He brings to Nemis Technologies a wide and balanced mix of competences; from business modelling and product development to commercial leadership expertise through international alliances and licensing deals, from business processes design to P&L management focused on the delivery of key financial and strategic objectives. He holds a Master in International Business from the Sorbonne University in Paris, an MBA from Ashridge School of Management (UK) and attended recently the Strategic Finance program at IMD business school in Lausanne.

Mario is a trained scientist with an entrepreneurial mindset. As an ETH Zurich graduate from the group of food microbiology, he brings an extensive expertise in the detection of foodborne pathogens. Experienced in the supervision of scientific projects, he has worked in multinational teams in Germany, Great Britain and Italy before moving to Switzerland in 2013. His background in molecular sciences combined with microbiology has led him to join Nemis to lead the R&D of the pathogen identification portfolio.

“The NEMIS project is adding a new pillar to microbiological detection with the potential to simplify processes and make cost effective solutions available locally around the world. This attractive mission drew me into joining the founding team”

Dr. Urs Breitenstein is a corporate finance and M&A professional with 20 years of experience. He works as part time CFO and Co-founder for Nemis Technologies AG.

Before co-founding Hoffmann & Partner, Dr. Breitenstein worked for Basler Kantonalbank, PricewaterhouseCoopers and, most recently, for Deloitte in Zurich, where he was a partner and team leader. He developed the valuation and business modelling team in Switzerland and was simultaneously responsible for the mergers and acquisitions department, where he led the life science industry group. Dr. Breitenstein has also worked on several international projects, providing him with outstanding expertise in complex cross-border assessments and corporate transactions.Dr. UrsBreitenstein studied at the graduate school of the Swiss National Bank in Gerzensee and holds a doctorate in economics (Dr. rer. pol.) from the University of Basel.

Daniel is a passionate engineer with a MSc in Microengineering and a CAS in Management of Biotech, Medtech and Pharma Ventures from the EPFL in Switzerland. In his past, he has developed mechanics, electronics and software for autonomous robots, worked on an arm-exoskeleton for the European Space Agency, was co-founder of a startup for aerial photography with drones, scaled-up digital 3D printing technologies for hearing aids, built manufacturing lines for pacemakers and was responsible for the end-to-end supply chain of an implantable pump to treat refractory ascites. He has 14 years of working experience in the medical device industry as a process owner, project- and team leader, consultant, production- and supply chain manager. As the member of a business angel network, Daniel is a seed investor of Nemis since 2018 and he joined the company as Head of Operations in February 2020.

“I was fascinated by this lean startup and the straightforward business plan. Nemis is launching a great technology platform in a growing market waiting for new solutions. Hygiene monitoring in the food industry and antibiotic resistance testing in clinical diagnostics are very important missions in a more and more globalized world. I am proud to be part of this endeavor.”

Franzisca studied economics at the University of St.Gallen and has a passion for addressing environmental and human issues in a holistic way.

In 2014, Franzisca founded and is since managing the organization “Lotus for Laos” (www.lotusforlaos.org), a social project with the purpose of enabling Laotian orphans to study at a local university. For about two years, she previously worked for the insurance Swiss Life, gaining insights and expertise in the areas of event management and marketing. She joined NEMIS in October 2018, inspired to further contribute to making this world a safer place.

Sophie Olvany is an economics student at the University of St. Gallen with an interest in sustainable development. She previously gained insight into the area of marketing at US non-profit ChangingThePresent, a start-up dedicated to popularizing donations to a variety of charitable causes as a replacement for traditional gifts. She joined Nemis in December 2019 with the aim of making a contribution to food safety worldwide.

James is a senior project manager and postdoctoral scientist with significant experience in the Swiss Biotechnology Industry. He has a Ph.D. in Food and Nutritional Sciences from the University of Reading, with extensive post-doctoral training in host-pathogen interactions at Imperial College London, and in Chemical Biology at EPFL. He has authored over 20 peer-reviewed publications, raised over 1M CHF in non-dilutive funding, and is highly skilled in Bacteriology and Pre-Clinical imaging. Since moving to Switzerland in 2015, he has been involved in several early-stage start-ups outside of the field of Microbiology, including development of Photodetection agents for Image-Guided Resection of Breast Cancer, and cutting-edge Single-Cell Molecular Diagnostics for Endometriosis.

Michelle is currently studying Business Administration at the University of St. Gallen and has already been able to put her gained knowledge to work. For 1.5 years she worked as a student trainee at UBS in the Global Family Office unit (formerly UHNW) and gained experience in organizing and coordinating through a multi-stakeholder approach. She was able to establish valuable contacts in the industry and launch projects related to sustainable and impact investing through her own initiative.

Michelle has a keen interest in global issues such as nutrition, energy transition, inequality and politics which is also evident in her passion for books. Through her curiosity, her experience and knowledge she would like to have a positive impact in her life.

Roger Meier is a seasoned early stage entrepreneur and company builder who assisted many start-up and growth companies and projects in their set-up, team building, talent and fund sourcing etc., mainly but not only in the life sciences sector. He is the founder and owner of Clarena Ltd., a company that serves corporates and executives in the fields of corporate finance, change management, coaching and HR. In his earlier career, he consulted mid to large sized multinational companies at Coopers & Lybrand (later PwC) in the field of financial and risk management. In the 80’s, he helped the US investment bank Salomon Brothers Inc. (in the US, UK and Switzerland) to establish a Swiss client base with institutional investors. Previously, he worked in a Geneva private bank in trading and in Private Banking at Swiss Bank Corp. in Basel. He holds a finance degree from the University of Applied Sciences in Basel.

Urs Spitz is a senior executive, entrepreneur and investor. He studied Organic Chemistry and Computer Science in Zürich, Chicago and Boston and has always remained a scientist at heart. Urs authored and co-authored dozens of patents and scientific publications. After his academic education, Urs gained an extensive professional experience as a consultant with Bain & Co. and as a business manager with the international group Mettler Toledo. Since 2004, he is leading the Biosynth group, a fine chemical manufacturer with sites in Switzerland and Slovakia and offices in the US and China. Urs is an active business angel focusing on early stage investments and board member of several innovative biotechnology companies, and now a co-founder of Nemis Technologies AG.